Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT: Secondary Prevention of Schizophrenia
2007-001573-28Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of aripiprazole in Clinical high risk for psychosis (CHR) and schizophrenia (2 arms), sponsored by University of Cologne. Primary endpoint: Transition to psychosis. Started Mar 2008; status: completed.
02
Drugs
aripiprazole
03
Conditions
Clinical high risk for psychosis (CHR)schizophrenia
Beyond the preview
Go deeper on 2007-001573-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001573-28.